Mikhail A. Kostylev

Mikhail A. Kostylev

Auto-generated profile, based on publicly available information

Mikhail A. Kostylev

Cellular Neuroscience, Neurodegeneration and Repair Program, Departments of Neurology and Neurobiology, Yale University School of Medicine, New Haven, CT, 06536, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2012 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
JUJi Won Um
Ji Won Um
HNHaakon B Nygaard
Haakon B Nygaard
JHJacqueline K Heiss
Jacqueline K Heiss
MKMikhail A Kostylev
Mikhail A Kostylev
MSMassimiliano Stagi
Massimiliano Stagi
SSStephen M Strittmatter
Stephen M Strittmatter
Here the authors show that the binding of amyloid-β (Aβ) oligomers to cellular prion protein (PrPc) activates Fyn kinase. Aβ stimulation of PrPc/Fyn signaling drives phosphorylation of the NR2B subunit of NMDA receptors, with a subsequent loss of receptor surface expression and dendritic spines. Amyloid-beta (Aβ) oligomers are thought to trigger Alzheimer's disease pathophysiology. Cellular prion protein (PrPC) selectively binds oligomeric Aβ and can mediate Alzheimer's disease–related phenotypes. We examined the specificity, distribution and signaling of Aβ-PrPC complexes, seeking to understand how they might alter the function of NMDA receptors (NMDARs) in neurons. PrPC is enriched in postsynaptic densities, and Aβ-PrPC interaction leads to Fyn kinase activation. Soluble Aβ assemblies derived from the brains of individuals with Alzheimer's disease interacted with PrPC to activate Fyn. Aβ engagement of PrPC-Fyn signaling yielded phosphorylation of the NR2B subunit of NMDARs, which was coupled to an initial increase and then a loss of surface NMDARs. Aβ-induced dendritic spine loss and lactate dehydrogenase release required both PrPC and Fyn, and human familial Alzheimer's disease transgene–induced convulsive seizures did not occur in mice lacking PrPC. These results delineate an Aβ oligomer signal transduction pathway that requires PrPC and Fyn to alter synaptic function, with deleterious consequences in Alzheimer's disease.

1 September 2013 in Neuron
Verified
Journal Article
Closed access
JUJi Won Um
Ji Won Um
AKAdam C. Kaufman
Adam C. Kaufman
MKMikhail Kostylev
Mikhail Kostylev
JHJacqueline K. Heiss
Jacqueline K. Heiss
MSMassimiliano Stagi
Massimiliano Stagi
SSStephen M. Strittmatter
Stephen M. Strittmatter

23 February 2015 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
AKAdam C. Kaufman
Adam C. Kaufman
SSSantiago V. Salazar
Santiago V. Salazar
LHLaura T. Haas
Laura T. Haas
JYJinhee Yang
Jinhee Yang
MKMikhail A. Kostylev
Mikhail A. Kostylev
SSStephen M. Strittmatter
Stephen M. Strittmatter

14 December 2015 in Brain
Verified
Journal Article
Open access
PDF file
LHLaura T. Haas
Laura T. Haas
SSSantiago V. Salazar
Santiago V. Salazar
MKMikhail A. Kostylev
Mikhail A. Kostylev
JUJi Won Um
Ji Won Um
AKAdam C. Kaufman
Adam C. Kaufman
SSStephen M. Strittmatter
Stephen M. Strittmatter
Alzheimer's disease-related phenotypes in mice can be rescued by blockade of either cellular prion protein or metabotropic glutamate receptor 5. We sought genetic and biochemical evidence that these proteins function cooperatively as an obligate complex in the brain. We show that cellular prion protein associates via transmembrane metabotropic glutamate receptor 5 with the intracellular protein mediators Homer1b/c, calcium/calmodulin-dependent protein kinase II, and the Alzheimer's disease risk gene product protein tyrosine kinase 2 beta. Coupling of cellular prion protein to these intracellular proteins is modified by soluble amyloid-β oligomers, by mouse brain Alzheimer's disease transgenes or by human Alzheimer's disease pathology. Amyloid-β oligomer-triggered phosphorylation of intracellular protein mediators and impairment of synaptic plasticity in vitro requires Prnp-Grm5 genetic interaction, being absent in transheterozygous loss-of-function, but present in either single heterozygote. Importantly, genetic coupling between Prnp and Grm5 is also responsible for signalling, for survival and for synapse loss in Alzheimer's disease transgenic model mice. Thus, the interaction between metabotropic glutamate receptor 5 and cellular prion protein has a central role in Alzheimer's disease pathogenesis, and the complex is a potential target for disease-modifying intervention.

1 July 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MKMikhail A. Kostylev
Mikhail A. Kostylev
AKAdam C. Kaufman
Adam C. Kaufman
HNHaakon B. Nygaard
Haakon B. Nygaard
PPPujan Patel
Pujan Patel
LHLaura T. Haas
Laura T. Haas
SSStephen M. Strittmatter
Stephen M. Strittmatter
Alzheimer's disease (AD) is characterized by Amyloid-β accumulation, with soluble oligomers (Aβo) being the most synaptotoxic. However, the multivalent and unstable nature of Aβo limits molecular characterization and hinders research reproducibility. Here, we characterized multiple Aβo forms throughout the lifespan of various AD mice, and in post-mortem human brain. Aβo exists in several populations, where Prion-Protein-(PrPC)-interacting Aβo is a high molecular weight Aβ assembly present in multiple AD mice and human AD. Levels of PrPC-interacting Aβo match closely with mouse memory, and are equal or superior to other Aβ measures in predicting behavioral impairment. However, Aβo metrics vary considerably between mouse strains. Deleting PrPC expression in mice with relatively low PrPC-interacting Aβo (Tg2576) results in partial rescue of cognitive performance as opposed to complete recovery in animals with a high percentage of PrPC-interacting Aβo (APP/PSEN1). These findings highlight the relative contributions and interplay of Aβo forms in AD.

5 May 2015 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
HNHaakon Nygaard
Haakon Nygaard
AKAdam C Kaufman
Adam C Kaufman
TSTomoko Sekine-Konno
Tomoko Sekine-Konno
LHLinda L Huh
Linda L Huh
HGHilary Going
Hilary Going
SSStephen M Strittmatter
Stephen M Strittmatter
Introduction: Recent studies have shown that several strains of transgenic Alzheimer’s disease (AD) mice overexpressing the amyloid precursor protein (APP) have cortical hyperexcitability, and their results have suggested that this aberrant network activity may be a mechanism by which amyloid-β (Aβ) causes more widespread neuronal dysfunction. Specific anticonvulsant therapy reverses memory impairments in various transgenic mouse strains, but it is not known whether reduction of epileptiform activity might serve as a surrogate marker of drug efficacy for memory improvement in AD mouse models. Methods: Transgenic AD mice (APP/PS1 and 3xTg-AD) were chronically implanted with dural electroencephalography electrodes, and epileptiform activity was correlated with spatial memory function and transgene-specific pathology. The antiepileptic drugs ethosuximide and brivaracetam were tested for their ability to suppress epileptiform activity and to reverse memory impairments and synapse loss in APP/PS1 mice. Results: We report that in two transgenic mouse models of AD (APP/PS1 and 3xTg-AD), the presence of spike-wave discharges (SWDs) correlated with impairments in spatial memory. Both ethosuximide and brivaracetam reduce mouse SWDs, but only brivaracetam reverses memory impairments in APP/PS1 mice. Conclusions: Our data confirm an intriguing therapeutic role of anticonvulsant drugs targeting synaptic vesicle protein 2A across AD mouse models. Chronic ethosuximide dosing did not reverse spatial memory impairments in APP/PS1 mice, despite reduction of SWDs. Our data indicate that SWDs are not a reliable surrogate marker of appropriate target engagement for reversal of memory dysfunction in APP/PS1 mice.